CareDx, Inc (CDNA)

Market Cap	910.93M
Revenue (ttm)	346.42M
Net Income (ttm)	62.08M
Shares Out	55.68M
EPS (ttm)	1.07
PE Ratio	15.23
Forward PE	22.53
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,579,165
Open	15.97
Previous Close	15.36
Day's Range	15.48 - 16.39
52-Week Range	7.42 - 34.84
Beta	2.27
Analysts	Buy
Price Target	30.33 (+85.39%)
Earnings Date	Apr 30, 2025

About CDNA

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to typ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 17, 2014
• Employees: 650
• Stock Exchange: NASDAQ
• Ticker Symbol: CDNA
• Website: https://caredx.com

Analyst Forecast

According to 7 analysts, the average rating for CDNA stock is "Buy." The 12-month stock price forecast is $30.33, which is an increase of 85.39% from the latest price.

Price Target

$30.33

(85.39% upside)

Analyst Consensus: Buy